Pharmaceuticals

Eton Pharmaceuticals

Eton Pharmaceuticals released FY2026 Q1 earnings on May 14 After-Market (EST), actual revenue USD 24.27 M (forecast USD 22.4 M), actual EPS USD 0.05 (forecast USD 0.09)

Eton Pharmaceuticals to release FY2026 Q1 earnings on May 14 After-Market EST, forecast revenue USD 22.4 M, EPS USD 0.09

Eton Pharmaceuticals released FY2025 Q4 earnings on March 19 After-Market EST, actual revenue USD 21.28 M (forecast USD 20.58 M), actual EPS USD 0.0515 (forecast USD 0.1033)

Eton Pharmaceuticals released FY2025 earnings on March 19 After-Market EST, actual revenue USD 79.95 M (forecast USD 79.27 M), actual EPS USD -0.1709 (forecast USD -0.1166)

Eton Pharmaceuticals to release FY2025 Q4 earnings on March 19 After-Market EST, forecast revenue USD 20.58 M, EPS USD 0.1033

Eton Pharmaceuticals released FY2025 9 Months Earnings on November 6 After-Market EST, actual revenue USD 58.67 M, actual EPS USD -0.2316

Eton Pharmaceuticals released FY2025 Q3 earnings on November 6 After-Market (EST), actual revenue USD 22.46 M (forecast USD 20.47 M), actual EPS USD -0.0716 (forecast USD 0.09)

Eton Pharmaceuticals to Release FY2025 Q3 Earnings on November 6 After-Market EST, Forecast Revenue USD 20.47 M, EPS USD 0.09

Eton Pharmaceuticals released FY2025 Semi-Annual earnings on August 7 After-Market (EST), actual revenue USD 36.21 M, actual EPS USD -0.1545

Eton Pharmaceuticals released FY2025 Q2 earnings on August 7 After-Market EST, actual revenue USD 18.93 M (forecast USD 16.71 M), actual EPS USD -0.1 (forecast USD -0.0366)

Eton Pharmaceuticals to Release FY2025 Q2 Earnings on August 7 After-Market EST, Forecast Revenue USD 16.71 M, EPS USD -0.0366

Eton Pharmaceuticals' New Drug Application Accepted by FDA

Eton Pharmaceuticals Inc. to be included in Russell 2000® and Russell 3000® indices

Eton Pharmaceuticals Releases Corporate Presentation

Eton Pharmaceuticals' COO Disposes Common Stock

Opaleye Management Reports Acquisition of Eton Pharmaceuticals Common Stock

Eton Pharmaceuticals Inc. holds annual shareholders' meeting

Eton Pharmaceuticals CEO Reports Stock Disposal

Eton Pharmaceuticals' KHINDIVI™ Oral Solution Approved by FDA

Eton Pharmaceuticals Announces CEO Changes

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

ETON

SBIO

IBBQ

LABU

Eton Pharmaceuticals has secured exclusive U.S. commercialization rights for IMPAVIDO, agreeing to pay $4.25 million in fixed fees and up to $4 million in sales milestones. Eton will share 55% of annual net sales up to $7 million and 50% above that. The agreement, effective from September 26, 2026, includes a term until March 31, 2032, with potential renewals. Symphony Health projects 2025 U.S. sales of $8.1 million.

TradingView

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

Ark Genomic Revolution ETF

iShares US Pharma

VanEck Biotech ETF

VG Health

Health Care Select Sector SPDR

iShares Global Healthcare

Invesco Nasdaq Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share

Eton Pharmaceuticals reported a 73% year-over-year increase in product revenue, reaching $24 million in Q1 2026. The company launched two new products and raised its full-year revenue guidance to exceed $120 million. Adjusted EBITDA for the quarter was $5.7 million, with a target of a 30% margin for the year and 50% by 2028. Eton is focusing on R&D projects and acquisitions to expand its rare disease portfolio, aiming for $200 million in annual revenue by 2027 and $500 million by 2030.

benzinga_article

Full Transcript: Eton Pharmaceuticals Q1 2026 Earnings Call

Earnings Watch

Eton Pharmaceuticals | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 24.27 M

Eton Pharmaceuticals | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 24.27 M

H.C. Wainwright analyst Swayampakula Ramakanth has maintained a Buy rating on Eton Pharmaceuticals (ETON) with a price target of $52.00, while the stock closed at $29.71. Ramakanth, a 5-star analyst, has an average return of 18.9% and a 43.31% success rate. Eton has a Strong Buy consensus with a price target of $41.00, indicating a 38% upside. Craig-Hallum also reiterated a Buy rating with a $40.00 target.

Tip Ranks

Mirum Pharmaceuticals

Corcept Therap

Evotec SE

H.C. Wainwright Remains a Buy on Eton Pharmaceuticals (ETON)

On May 12, 2026, in Deer Park, Illinois, Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a pharmaceutical company specializing in rare disease treatments, revealed that its executive team will attend three investor conferences.

Unusual Whales

Eton Pharmaceuticals to Participate in Upcoming Investor Conferences

Eton Pharmaceuticals (NASDAQ:ETON) reached a new 12-month high of $29.80, closing at $28.90 with significant trading volume. Analysts have mixed ratings: HC Wainwright raised its price target to $52 (buy), while Weiss Ratings maintained a sell rating. The company reported $21.28 million in revenue but missed EPS estimates. Institutional investors hold 27.86% of shares. Eton focuses on developing pharmaceutical products for rare diseases and has a market cap of $790.70 million.

Eton Pharmaceuticals(ETON.US)